poster

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

10/26/2023

Left Frontal lobe Meningioma masquerading as Schizophrenia

Frontal lobe tumors are known to alter whole personality, not just memory and retention. They are not easily suspected and missed in patients diagnosed with a psychiatric disorder. We pre...

10/26/2023

Improvements in Depressive Symptoms in Patients With Major Depressive Disorder: Analysis of Zuranolone Efficacy From 4 Randomized, Placebo-Controlled Trials

An analysis of 4 randomized, placebo-controlled trials evaluating a 14-day treatment course of zuranolone 30- or 50-mg in adults with MDD showed nominally significant improvements (p ...

10/26/2023

Incidence and Characteristics of Akathisia With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder

Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...

10/26/2023

Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement—An Interactive Digital Platform to Educate on Schizophrenia Care

Educational initiatives targeting common clinical dilemmas encountered by clinicians managing patients with schizophrenia may clarify appropriate use of long-acting injectable antipsychot...

10/26/2023

Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study

AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...

10/26/2023

Improvements in Daytime Functioning With Lemborexant Treatment

Daytime impairment can be assessed by items 4-7 of the 7-item Insomnia Severity Index. Here we report the impact of lemborexant (LEM) versus placebo on shifts in daytime-function-specific...

10/26/2023

Impact of Lemborexant on Daytime Sleepiness/Alertness in Subjects With Insomnia Disorder and Baseline Sleepiness

Some sleep medications may cause morning sleepiness due to sedative side effects. This post-hoc analysis of Study 304 showed that lemborexant (LEM), a competitive dual orexin receptor ant...

10/26/2023

Impact of Treatment With TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), at Different Stages of Schizophrenia: a Post Hoc Analysis

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that has been shown to reduce time to impending relapse in patients with schizophreni...

10/26/2023

Implementation of Exercise Reminders to Improve Symptoms of Clinical Depression

This poster is part of the requirement in fulfillment of a Doctor of Nursing Practice (DNP) degree at Rutgers University, School of Nursing. The purpose of the project is to improve the s...

10/26/2023

Tracks

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products